Introduction
Lipoprotein(a) (Lp(a)) elevation is a strong and independent risk factor for cardiovascular disease (CVD). 1 Mendelian randomization studies support a causal role for Lp(a) in CVD. [2] [3] [4] Despite the fact that Lp(a) measurement is recommended in patients at intermediate risk in the European Society of Cardiology (ESC)/ European Atherosclerosis Society (EAS) guidelines, 5, 6 none of the guidelines recommend specific therapeutic interventions in case of high Lp(a) levels due to the absence of evidence for effective therapeutic interventions. Specific Lp(a) lowering strategies are being developed, but have not been tested in clinical outcome studies. In view of a 60% low-density lipoprotein cholesterol (LDL-C) lowering 7 combined with a 30% Lp(a) lowering 8 effect, proprotein convertase subtilisin/ kexin Type 9 (PCSK9) inhibitors have been put forward as potential therapeutic strategy in patients with Lp(a) elevation. However, the moderate Lp(a) reduction by PCSK9 inhibitors is clearly insufficient to lower high Lp(a) levels to below the currently accepted Lp(a) threshold. 9 Interestingly, previous studies suggested that elevated Lp(a) confers risk predominantly in conjunction with elevated levels of LDL-C. 10, 11 However, it remains a matter of debate whether very low LDL-C levels will result in attenuation of the Lp(a)-mediated CVD risk despite persistent Lp(a) elevation. Given the proposed potentiation of the CVD risk between LDL-C and Lp(a), we hypothesized that the risk associated with elevated Lp(a) levels would largely be attenuated at lower LDL-C levels. We tested this hypothesis in two large studies corresponding to a primary prevention setting: the European Prospective Investigation of Cancer (EPIC)-Norfolk prospective population study and the Copenhagen City Heart Study (CCHS) prospective population study.
Methods

Study design
The EPIC-Norfolk prospective population study consists of 25 633 individuals recruited from general practices in the Norfolk area, UK. 12 Study participants aged between 39 and 79 were enrolled between 1993 and 1997. At baseline, patients completed general health questionnaires and a panel of measurements was performed. During follow-up, all individuals were flagged for mortality at the UK Office of National Statistics, and vital status was ascertained for the entire cohort. Data on all hospital contacts throughout England and Wales were obtained using National Health Service numbers through linkage with the East Norfolk Health Authority (ENCORE) database. Hospital records and death certificates were coded by trained nosologists and categorized according to the International Classification of Disease 10th revision (ICD-10). Death or hospitalizations were attributed to atherosclerotic CVD if the ICD-10 codes I20-I25 or I60-69 were recorded as the underlying cause of death or the reason for hospitalization. These ICD-10 codes represent the American College of Cardiology (ACC)/American Heart Association (AHA) definition of atherosclerotic CVD and include coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke. 13 The study protocol was approved by the Norwich District Health Authority Ethical Committee. All individuals gave written informed consent. The CCHS consists of 24 260 individuals and is a prospective study of the Danish general population initiated in 1976-78 with follow-up examinations in 1981-83, 1991-94, and 2001-03. For this study, 9448 participants from the 1991 to 1994 and 2001 to 2003 examinations were included with known Lp(a) and LDL-C levels. Individuals were recruited using the Danish Civil Registration System to best reflect the white Danish general population aged 20-100þ years. Participants filled out a questionnaire including lifestyle, medical-, and family history and went through a physical examination including blood sampling, and measurement of blood pressure, height, and weight. In Denmark, each individual is assigned a Civil Registration Number at birth and all individuals were followed through the national Danish Patient Registry and the national Danish Causes of Death Registry to ascertain diagnosis of atherosclerotic CVD including non-fatal myocardial infarction, coronary heart disease death, and fatal or non-fatal stroke using ICD-8 codes 410-414 and 430-438, and ICD-10 codes I20-I25 and I60-I68, respectively, and validated as  described. 2,14,15 The CCHS was approved by Danish ethics committees, all individuals gave written informed consent, and the study was conducted according to the declaration of Helsinki.
Biochemical analysis
In EPIC-Norfolk, non-fasting blood 16 was drawn at baseline from study individuals, and total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were determined with the RA1000 analyzer (Bayer Diagnostics, Basingstoke, UK). The Friedewald formula was used for the calculation of LDL-C levels. 17 The remaining plasma was stored at -80 C for future analyses. In 2010, samples were thawed and Lp(a) was measured on an Olympos AU640 analyzer with Randox reagents (Randox Laboratories Ltd, Crumlin, County Antrim, UK). The rs10455872 genetic variant was genotyped using Custom TaqMan V R SNP Genotyping Assays (Applied Biosystems, Warrington, UK).
For the CCHS, standard hospital assays were used to measure triglycerides, total cholesterol, and HDL-C on fresh non-fasting 16 plasma samples at baseline. Low-density lipoprotein cholesterol was calculated using the Friedewald equation when plasma triglycerides were <4 mmol/L (352 mg/dL), and otherwise measured by a direct assay. Individuals from the CCHS examination in 1991-94 had Lp(a) total mass measured by an isoform insensitive turbidimetric in-house assay as described previously. 18 
Statistical analysis
Parallel statistical analyses were performed for EPIC-Norfolk and the CCHS, but independent of each other. For this study, individuals with myocardial infarction or stroke prior to baseline screening were excluded. Also, individuals missing LDL-C or Lp(a) levels, those who were on lipid-lowering therapy at baseline, or non-Caucasian individuals were excluded. Two Lp(a) categories were constructed based on the EAS proposed threshold for Lp(a), 9 with the cut-off set at the 80th cohort percentile, thereby dividing people in groups with Lp(a) levels <80 and > _80th cohort percentile in both cohorts. Low-density lipoprotein cholesterol was corrected for Lp(a)-derived cholesterol (LDL-C corr ) 19 and cut-offs were set at 2.5, 3.5, 4.5, and 5.5 mmol/L, dividing people in groups with LDL-C corr levels <2.5, 2.5-3.49, 3.5-4.49, 4.5-5.49, and > _5.5 mmol/L. Individuals were categorized using these Lp(a) and LDL-C corr cut-offs. Multivariable (age-, sex-, smoking-, body mass index-, diabetes mellitus-, systolic blood pressure, and glomerular filtration rate-) adjusted hazard ratios (HRs) were calculated for each category and the category with LDL-C <2.5 mmol/L and Lp(a) <80th cohort percentile was used as reference category. To strengthen clinical applicability of our findings, we also calculated multivariable adjusted HRs for laboratorymeasured (non-Lp(a) adjusted) LDL-C using the EAS proposed Lp(a) threshold of 50 mg/dL 9 and 30 mg/dL. 20 Trend lines were constructed for both Lp(a) categories. A Coxregression analysis was performed to test for interaction between the five LDL-C corr groups (<2.5, 2.5-3.49, 3.5-4.49, 4.5-5.49, and > _5.5) and the two Lp(a) groups (<80th vs. > _80th cohort percentile) on the risk of CVD. All statistical analyses were performed using SPSS (Version 24.0, IBM Corporation, Armonk, NY, USA), GraphPad Prism (version 5, GraphPad Software, Inc., CA, USA), or STATA (version 13.1, StataCorp, TX, USA). In EPIC-Norfolk, the mean age was 59.0 ± 9.1 and 58.9 ± 9.0 for individuals with an Lp(a) of <80 and > _80th cohort percentile. Mean LDL-C corr levels were 3.8 (±1.0) and 3.6 (±0.9) mmol/L for the respective categories. Median (interquartile range) Lp(a) levels were 9.6 (5.6-17.3) and 45.4 (35.2-59.1) mg/dL for individuals with an Lp(a) <80 and > _80th cohort percentile. The total number of CVD events was 3347, namely 1879 non-fatal myocardial infarctions, 920 deaths due to coronary heart disease, 646 non-fatal strokes, and 161 fatal strokes. In CCHS, the mean age was 58.1 ± 16 and 59.5 ± 15 for individuals with an Lp(a) <80 and > _80th cohort percentile, respectively. Mean LDL-C corr levels were 3.5 (±1.1) and 3.3 (±1.1) mmol/L for the respective categories. Median (interquartile range) Lp(a) levels were 12.0 (4.1-24.4) and 84.0 (63.3-118) mg/dL for individuals with an Lp(a) <80 and > _80th cohort percentile. The total number of CVD events were 2577, namely 1347 non-fatal ischaemic heart disease, 393 deaths due to coronary heart disease, 684 non-fatal strokes, and 153 fatal strokes. The CVD risks associated with the Lp(a) category <80 and > _80th cohort percentile and the five LDL-C corr categories are presented in Tables 3 and 4 for EPIC-Norfolk and the CCHS. The CVD risks associated with the Lp(a) category <50 and > _50 mg/dL and the five laboratory-measured LDL-C categories are provided in Supplementary material online, Table S1A and S1B.
Results
Lipoprotein
Among individuals in EPIC-Norfolk with an Lp(a) <80th cohort percentile, those with an LDL-C corr > _5.5 mmol/L had a CVD risk HR [95% confidence interval (CI); P-value] of 1.61 (1.29-2.00; P < 0.001) compared with those with an LDL-C corr <2.5 mmol/L ( Table 3) . In individuals with an Lp(a) > _80th cohort percentile (and compared with individuals with an Lp(a) <80th percentile and LDL-C corr <2.5 mmol/L), those with an LDL-C corr > _5.5 mmol/L had a CVD HR of 2.17 (1.58-2.98; P < 0.001) whereas those with an LDL-C corr <2.5 mmol/L had a HR of 1.11 (0.77-1.59; P = 0.57). Comparable results for the impact of Lp(a) on CVD risk in the various laboratorymeasured LDL-C categories were obtained using the 50 mg/dL (87th percentile) and 30 mg/dL (77th percentile) cut-off (Supplementary material online, Tables S1A and S2A).
Among individuals in the CCHS with Lp(a) <80th cohort percentile, the HRs for individuals with a LDL-C corr of > _5.5 mmol/L was 1.42 (1.15-1.74; P < 0.001), compared with individuals with an LDL-C corr of <2.5 mmol/L ( Table 4) . In individuals with an Lp(a) > _80th cohort percentile (and compared with individuals with an Lp(a) <80th percentile and LDL-C corr <2.5 mmol/L), those with an LDL-C corr > _5.5 mmol/L had a HR of 2.34 (1.63-3.35; P < 0.001) while those with an LDL-C corr <2.5 mmol/L had a HR of 1.08 (0.85-1.38; P = 0.48). Results for laboratory-measured LDL-C and Lp(a) cut-off <50 (80th percentile) and > _50 mg/dL were comparable and can be found in Supplementary material online, Table S1B. Using the 30 mg/ dL Lp(a) cut-off, which represents the 67th cohort percentile, resulted in non-significant results in all LDL-C categories <5.5 mmol/L for Lp(a) <30 mg/dL and <4.5 mmol/L for Lp(a) > _30 mg/dL (Supplementary material online, Table S2B ).
There was no significant interaction between LDL-C corr and Lp(a) levels on CVD risk in either cohort (P-value of 0.80 and 0.11 in EPICNorfolk and CCHS, respectively). The risk of CVD for each Lp(a) category is shown in Figure 1 . For EPIC-Norfolk, the slope [± standard deviation (SD); 
Discussion
Our study in two prospective population cohorts corresponding to a primary prevention setting, the EPIC-Norfolk and the CCHS, confirms that both LDL-C and Lp(a) are independently associated with CVD risk. Individuals with high Lp(a) levels are characterized by a markedly increased CVD risk compared with individuals with lower Lp(a) levels. 9 As expected, the absolute CVD risk is substantially lower in subjects with elevated Lp(a) and low LDL-C levels compared with subjects with elevated Lp(a) and high LDL-C levels. More importantly, the CVD risk increase conveyed by Lp(a) appeared to diminish at the lowest LDL-C levels. However, there was no significant interaction between LDL-C corr and Lp(a) levels on CVD risk in either cohort, implying that elevated Lp(a) and elevated LDL-C are associated with increased CVD risk independent of the level of the other risk factor. When evaluating the roles of LDL-C and Lp(a) on CVD-risk, it is essential to first consider the details of these parameters. For LDL-C, recent data have emphasized the contribution of cholesterol in the Lp(a) fraction to the laboratory-measured LDL-C. 19 Although this Data are presented as age-, sex-, smoking-, body mass index-, diabetes mellitus-, systolic blood pressure-, glomerular filtration rate-adjusted hazard ratios for the 80th cohort percentile for Lp(a) with corresponding 95% confidence interval limits. LDL-C, low-density lipoprotein cholesterol; LDL-C corr , low-density lipoprotein cholesterol corrected for Lp(a)-derived cholesterol (mmol/L); Lp(a), lipoprotein(a) (mg/dL). contribution is negligible in individuals with low Lp(a) levels, it can cumulate up to 50% of the laboratory-measured cholesterol in the LDL-C fraction in individuals with elevated Lp(a). 19 To avoid a disproportionate impact of Lp(a)-C particularly in individuals with low LDL-C levels, the Lp(a)-corrected LDL-C was therefore used in our interaction analyses. The threshold used to define Lp(a) elevation is a matter of debate. The absolute cut-off of 50 mg/dL represents different percentile values: the 87th percentile in EPIC-Norfolk and the 80th percentile in CCHS cohort. This discrepancy most likely reflects the difficulties in measuring Lp(a) with marked heterogeneity between different Lp(a) assays. 21 Hence, inter-assay variation between the EPIC-Norfolk and CCHS may have occurred, which may impact on the interpretation of previous studies 22 , and therefore, hamper the use of absolute cut-offs for Lp(a) in routine clinical practice.
Observational studies on low-density lipoprotein cholesterol and lipoprotein(a) interaction
Several observational studies support that Lp(a) only increases CVD risk if LDL-C levels exceed a certain threshold. In 500 subjects without CVD in the Bruneck study, elevated Lp(a) (>32 mg/dL) was only a predictor for CVD risk in subjects with LDL-C levels > _3.3 mmol/L. 23 In 9133 participants of the PRIME study, elevated levels of Lp(a) (> _33 mg/dL) were associated with coronary heart disease only in individuals with LDL-C levels higher than 3.7 mmol/L. 24 Among 27 791 women of the Women's Health Study elevated Lp(a) levels (> _44 mg/dL) were associated with future cardiovascular (CV) events only in women with an LDL-C above 3.1 mmol/L. 11 In a meta-analysis of prospective studies, comprising 126 634 individuals, 1SD increase of Lp(a) was associated with CVD only in individuals with a non-HDL cholesterol >3.8 mmol/L 1 ; although no interaction was found between the non-HDL cholesterol tertiles, Lp(a), and CVD. Our results substantiate that in a primary prevention setting subjects with elevated Lp(a) levels, not using lipid-lowering therapy, at most have a very modest increase in CV-risk when LDL-C is below 2.5 mmol/L.
Intervention studies on low-density lipoprotein cholesterol and lipoprotein(a) interaction
In interventional studies, data on the relationship between LDL-C lowering on CVD risk in patients with high Lp(a) is equivocal. In 3877 individuals of the JUPITER trial treated with rosuvastatin and an achieved median LDL-C of 1.4 mmol/L, elevated Lp(a) (> _50 mg/dL) lost its significance for CVD risk, although it still had a nominally high HR (95% CI) of 1.67 (0.93-3.02). 25 In a post hoc analysis of the DAL-OUTCOMES study comprising 4139 acute coronary syndrome patients treated with dalcetrapib or placebo on top of statins and a mean LDL-C of 1.9-2.1 mmol/L, elevated Lp(a) levels (> _50 mg/dL) were also not associated significantly with adverse cardiovascular outcomes although it still had a nominally high HR (95% CI) of 1.16 (0.97-1.39). 26 Other studies reported a persistent CVD risk increase for individuals with elevated Lp(a), independent of LDL-C lowering interventions. In 411 individuals who underwent a percutaneous coronary intervention and achieved LDL-C levels <2.6 mmol/L, elevated levels of Lp(a) (> _30 mg/dL) were still associated with all-cause mortality and acute coronary syndromes. 27 When combining data from sub-populations of the JUPITER trial with data from the AIM high and LIPID trials, elevated levels of Lp(a) were also associated with increased CVD risk, independent from achieved LDL-C levels and/or use of lipid-lowering therapy. 28 However, in the latter analysis, persistent risk increase by Lp(a) elevation was observed particularly in the secondary prevention study (AIM-HIGH) irrespective of placebo or nicotinic acid therapy. 28, 29 When determining the effect of Lp(a) elevation only in the rosuvastatin treated patients, there was no longer a significant effect on CVD risk although it still had a nominally high odds ratio (95% Mean LDL-C corr levels apply to both Lp(a) categories. *P < _ 0.05, **P < 0.01, ***P < 0.001. Table 3) . This translates into a CVD risk reduction of 23% and 11%, respectively for every mmol/L of LDL-C decrease in the low-and high Lp(a) category, which is comparable with the 20% lower risk per mmol/L LDL-C reduction of the CTT collaboration meta-analysis. 30 However, combined with our observation that Lp(a) no longer conveys a substantial risk increase at low LDL-C levels in a primary prevention setting, this data supports the concept that potent LDL-C lowering is the primary target to lower absolute risk also in individuals with elevated Lp(a). Compounds offering significant Lp(a) reduction, comprising the PCSK9-antibodies 8 and the emerging apo(a)-antisense, 33 can be considered to further reduce residual Lp(a)-mediated risk. Besides the LDL-C lowering effect of 60-65%, PCSK9 antibodies offer a concomitant reduction of Lp(a) with 25-30%. 8 Post hoc analyses in FOURIER, 34 and ODYSSEY 35 trials will reveal to what extent PCSK9-antibody therapy is able to reduce CVD risk in patients with very high Lp(a), which will provide valuable information for the future position of the more potent apo(a) antisense therapy in high-risk patients.
Study limitations
Our study has several limitations, which merit closer consideration. First, the prevalence of subjects with LDL-C levels below 2.5 mmol/L is relatively low resulting in a limited number of elevated Lp(a) subjects in this category (229 and 453 in EPIC-Norfolk and CCHS, respectively), which may have led to loss of power to detect a significant effect of Lp(a) on CVD risk in this category. Second, the cut-off values used in our primary analyses concern the use of Lp(a)-corrected LDL-C combined with the 80th percentile cut-off for Lp(a) elevation. Although this represents the scientifically most sound approach, these values do not resonate with routine clinical practice. When using uncorrected, laboratory-measured LDL-C combined with the absolute cut-off of >50 mg/dL for Lp(a), the conclusions were however similar. Third, our analysis included mainly primary prevention subjects, with a low to moderate CVD-risk. As a change in CVD-risk following modification of a single risk factor depends heavily on the absolute baseline risk, 36 we cannot extrapolate our finding of a decreased Lp(a) influence at very low LDL-C levels to the higher risk groups such as patients after an acute coronary syndrome and individuals with familial hypercholesterolaemia or diabetes. In summary, our analyses in the primary prevention setting of EPIC-Norfolk and CCHS general population cohorts substantiate that LDL-C and Lp(a) are independently associated with CVD risk. However, at LDL-C levels <2.5 mmol/L, the CVD risk associated with elevated Lp(a) is attenuated. Prospective evaluation of the impact of robust LDL-C lowering vs. routine statin therapy combined with Lp(a) lowering strategies on CVD risk in high-risk patients with elevated Lp(a) levels is warranted to substantiate external validity of our findings in a high-risk secondary prevention setting.
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